^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RUNX1 (RUNX Family Transcription Factor 1)

    i
    Other names: RUNX1, RUNX Family Transcription Factor 1, Runt-Related Transcription Factor 1, Polyomavirus Enhancer-Binding Protein 2 Alpha B Subunit, SL3/AKV Core-Binding Factor Alpha B Subunit, SL3-3 Enhancer Factor 1 Alpha B Subunit, Runt Related Transcription Factor 1, Acute Myeloid Leukemia 1 Protein, Oncogene AML-1, PEBP2-Alpha B, PEA2-Alpha B, AMLCR1, CBFA2, AML1, Core-Binding Factor Subunit Alpha-2, AML1-EVI-1 Fusion Protein, Acute Myeloid Leukemia 1, Aml1 Oncogene, CBF-Alpha-2, AML1-EVI-1, PEBP2alpha, CBF2alpha, PEBP2aB, PEBP2A2, EVI-1, RUNX1
    1d
    Efficacy and safety of venetoclax-cytarabine-homoharringtonine-based cytoreductive therapy before allogeneic hematopoietic stem cell transplantation in refractory/relapsed acute myeloid leukemia with RUNX1::RUNX1T1: a retrospective study (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    All patients remained disease-free, with no events of measurable residual disease (MRD) positivity by flow cytometry or molecular analysis documented. These findings preliminarily confirm that venetoclax, cytarabine, and homoharringtonine-based cytoreductive therapy is a safe and effective bridging therapy for allo-HSCT in patients with refractory/relapsed AML and RUNX1::RUNX1T1 fusion gene.
    Retrospective data • Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)
    |
    RUNX1-RUNX1T1 fusion
    |
    Venclexta (venetoclax) • cytarabine • Synribo (omacetaxine mepesuccinate)
    3d
    Genetic Variation and Inflammation Intersections: GATA2- and RUNX1-Linked Mechanisms of Blood Pathogenesis. (PubMed, Exp Hematol)
    Corrupted signaling networks caused by the deleterious combination of inflammation and CP variation intersect with and disrupt physiological mechanisms governing hematopoietic stem and progenitor cell genome function. This review considers how inflammation triggers or amplifies the functional ramifications of CP variation as a blood pathogenic mechanism, with a particular emphasis on GATA2 and RUNX1 transcription factor-linked mechanisms.
    Review • Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • GATA2 (GATA Binding Protein 2)
    4d
    Integrated Multi-Omic Analysis Reveals Novel Subtype-Specific Regulatory Interactions in Pediatric B-Cell Acute Lymphoblastic Leukemia. (PubMed, Cancers (Basel))
    By integrating multiple -omics modalities, we identify not only features of interest but also begin to unravel the regulatory interactions driving subtype-specific mechanisms of leukemogenesis. This integrated analytic approach paves the way for enhanced precision medicine for precise subtyping and treatment selection for pediatric leukemia patients.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6)
    5d
    T cell development from expanded hematopoietic progenitors reveals initiation control by Lmo2 and Flt3L priming. (PubMed, Sci Immunol)
    Among 23 factors tested, Lmo2 knockout greatly accelerated the onset of germline TCR-Cβ locus transcription and expression of Tcf7, Gata3, and Runx1 and their targets. Thus, normal endogenous expression of this progenitor- and leukemia-associated factor markedly restrains T cell program initiation.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • LMO2 (LIM Domain Only 2) • GATA3 (GATA binding protein 3) • TCF7 (Transcription Factor 7)
    5d
    Characterization of Acute Myeloid Leukemia With t(16;21) Translocation: Cytogenetic, Molecular, and Immunophenotypic Findings. (PubMed, World J Oncol)
    The t(16;21)(p11;q22) translocation was the most frequently reported and was frequently associated with CD56 expression. The findings suggest that patients with t(16;21)(p11;q22) exhibited lower 5-year survival compared with the other group, highlighting the unfavorable outcomes observed in reported cases.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • CD34 (CD34 molecule) • NCAM1 (Neural cell adhesion molecule 1) • FUS (FUS RNA Binding Protein) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • ANPEP (Alanyl Aminopeptidase, Membrane)
    5d
    Integrating Gene Expression With Recurrent Mutations Improves Age-Stratified Risk Prediction in Acute Myeloid Leukemia. (PubMed, EJHaem)
    Although treatment variables were not included and analysis focused on selected genes, these findings support incorporation of expression-based features into genetic risk models and warrant prospective validation. The authors have confirmed clinical trial registration is not needed for this submission.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • MCL1 (Myeloid cell leukemia 1) • CHEK2 (Checkpoint kinase 2) • CCNG1 (Cyclin G1)
    |
    TP53 mutation • NPM1 mutation
    5d
    Phenocopies in acute lymphoblastic leukemia: Redefining leukemia subtypes in the transcriptomic era. (PubMed, Blood Rev)
    Adoption remains constrained by RNAseq availability, expertise and lesion-centric regulation. Prospective studies are needed to establish the clinical utility of newly described phenocopies, extending the advances made in subclassification and targeted treatment of BCR::ABL1-like ALL.
    Review • Journal
    |
    ABL1 (ABL proto-oncogene 1) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • ZNF384 (Zinc Finger Protein 384)
    5d
    Acute myeloid leukaemia (AML) harbouring KMT2A-PTD: should it be considered as a myelodysplasia-related abnormality? (PubMed, J Clin Pathol)
    AML harbouring KMT2A-PTD frequently displays MR immunophenotypic abnormalities and is frequently associated with AML-MR type mutations. In addition, they have similar outcomes as compared with AML-MR.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD7 (CD7 Molecule) • CD177 (CD177 Molecule)
    |
    IDH2 mutation • IDH2 R172
    6d
    Targeting oncogene-induced senescence in ETV6::RUNX1 pre-leukemic cells. (PubMed, Cell Death Discov)
    Furthermore, using Sca1-E::R transgenic mice, we validated E::R-induced OIS in the pre-leukemic Lin-Sca1+ immature population and observed reduced pre-B colony formation after SSK1 treatment. These findings demonstrate E::R's dual role in inducing OIS and conferring apoptosis resistance, highlighting the potential of senescence-targeted therapies to prevent leukemia progression and relapse in E::R carriers.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • CASP3 (Caspase 3)
    7d
    Case Report: Safety analysis of blinatumomab consolidation therapy in two cases of acute B-cell lymphoblastic leukemia in complete remission complicated with immune effector cell-associated neurotoxicity syndrome. (PubMed, Front Oncol)
    Therapy was continued without interruption, and symptoms resolved with levetiracetam intervention. The use of blinatumomab requires careful balancing of efficacy and neurotoxicity, particularly in high-risk patients. This case report provides valuable insights for the clinical recognition and management of ICANS.
    Journal
    |
    TP53 (Tumor protein P53) • DNMT3A (DNA methyltransferase 1) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • IL6 (Interleukin 6)
    |
    TP53 mutation
    |
    Blincyto (blinatumomab)
    9d
    Prognostic impact of myelodysplasia-related gene mutations in ELN-2022 favorable-risk acute myeloid leukemia subtypes. (PubMed, Ann Med)
    The presence of a single MRG mutation did not confer a worse prognosis in favorable-risk AML, whereas a high MRG mutation burden (≥2 mutations) was independently associated with poorer LFS. This study suggests that quantifying the MRG mutation burden may inform risk stratification in this patient population.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • ETV6 (ETS Variant Transcription Factor 6) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    TMB-H • ASXL1 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation